India, Nov. 3 -- MediWound Ltd. (MDWD), an enzymatic therapeutics developer for tissue repair, announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC, under which the underwriter will purchase 1.20 million shares of MediWound at a public price of $12.50 per ordinary share.
The gross proceeds are expected to be approximately $15 million. The offering is expected to close on or about November 5, 2026.
MediWound intends to use the net proceeds from the offering for working capital and general corporate purposes.
In addition, MediWound has granted to the underwriter a 30-day option to purchase up to an additional 180,000 ordinary shares at the public offering price less underwriting discounts and commiss...